23andMe : R&D Day 2022 Presentation

23andMe R&D Day

January 18, 2022

Disclaimer

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe's businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this presentation, including statements regarding 23andMe's strategy, financial position, funding for continued operations, cash reserves, projected costs, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," "schedule," and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe's current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe's forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also 8-K filed with the Securities and Exchange Commission ("SEC") on June 21, 2021 and in 23andMe's Current Report on Form 10-Q filed with the SEC on November 10, 2021, as well as other filings made by 23andMe with the SEC from time to time. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Except as required by law, 23andMe does not undertake any obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

Intellectual Property

All rights to the trademarks, copyrights, logos and other intellectual property listed herein belong to their respective owners 23andMe's use thereof does not imply an affiliation with, or endorsement by the owners of such trademarks, copyrights, logos and other intellectual property. Solely for convenience, trademarks and trade names referred to in this Presentation may appear with the ® or ™ symbols, but such references are not intended to indicate, in any way, that such names and logos are trademarks or registered trademarks of 23andMe.

Industry and Market Data

This Presentation relies on and refers to certain information and statistics based on 23andMe's management's estimates, and/or obtained from third party sources which it believes to be reliable. 23andMe has not independently verified the accuracy or completeness of any such third party information.

Copyright © 2022 23andMe, Inc.

2

Agenda

Introduction -- Anne Wojcicki, CEO and Co-Founder

23andMe Therapeutics

Therapeutics program overview - Kenneth Hillan, Head of Therapeutics

Target discovery vision - Joe Arron, Chief Scientific Officer, Therapeutics

Genetics-based target discovery - Adam Auton, VP of Human Genetics

CD200R1 immuno-oncologyprogram - Jennifer Low, Head of Therapeutics Development and Adrian Jubb, Sr. Clin. Dev. Fellow, Therapeutics CD96 immuno-oncologyprogram - Jennifer Low, Head of Therapeutics Development

Using genetics to inform clinical development - Jennifer Low, Head of Therapeutics Development

Therapeutics program concluding remarks - Kenneth Hillan, Head of Therapeutics

23andMe Consumer

Genetics-basedprimary care - Paul Johnson, VP, General Manager, Consumer

The power of polygenic risk scores (PRS) for personalized health - Geoff Benton, Director, Product R&D

Delivering a genetic-based primary care service - Davis Liu, Chief Clinical Officer

Concluding Remarks - Anne Wojcicki, CEO and Co-Founder

Q&A

Copyright © 2022 23andMe, Inc.

3

Introduction

Anne Wojcicki

CEO and Co-Founder

Copyright © 2022 23andMe, Inc.

4

Today's News on 23andMe and GSK Collaboration

• GSK has elected to extend the exclusive target discovery period of the collaboration for a fifth year
• • We will continue to discover and validate novel drug targets using 23andMe's proprietary genetic and health survey database
  • 23andMe will receive a one-time payment of $50 million

• 23andMe elects for royalty option on collaboration program targeting CD96
• • 23andMe will be eligible to earn tiered worldwide royalties up to the low double digits
  • The worldwide royalty option curtails 23andMe's future investment in this program and provides 23andMe with a potentially high value revenue stream if the program is successful

Copyright © 2022 23andMe, Inc.

5